Add immunotherapy to a new type of inhibitor that is directed to multiple forms of the genetic mutation that causes cancer Kras He kept pancreatic cancer in preclinical models during the same therapy directed by itself, according to researchers at the Perelman Faculty of Medicine of the University of Pennsylvania and the Abramson Cancer Cancer Center of Penn Medicine. The results, published in Cancer discoveryPrime the combination strategy for future clinical trials.
Combat the “Indian” genes “
Patients with pancreas cancer have a bad general prognosis: in most patients, the disease has already spread at the time of diagnosis, resulting in limited treatment options. Almost 90 percent of pancreatic cancers are driven by Kras Mutations, the genetic mutation that causes the most common cancer in cancer types, which researchers considered “Indians” for a long time. In 2021, the first Kras The inhibitor was approved to treat non -small cell lung cancer with KRAS G12C mutations, but with longer follow -up, it has been clear that Kras-The mutant cancers can quickly evolve to resist therapies aimed at a specific form of gene mutation.
“We have been excited about the perspective of Ras The inhibition of pancreatic cancer, which remains one of the most fatal and difficult to treat forms of cancer, “said the senior author of Co-Acorrente Ben Stanger, MD, PHD, Hanna Wise’s professor in cancer research and director of the Penn pancreatic cancer research center.” While the first wave of the wave of the wave of Kras Inhibitors have had a limited impact on cancer attention, this research shows that newer Ras Inhibition tools can have an immune stimulating effect, which makes them ideal to match immunotherapy for a longer and better treatment response. “
Previous investigations led by Stanger and Robert Vonderheide, MD, DPHIL, director of the Abramson Cancer Center, who also corresponds to the author in this study, showed that a small molecule inhibitor directed specifically KRAS G12D, The shape of the mutation that is most commonly found in pancreatic cancer stimulated the immune system by reducing tumors or stopping cancer growth in preclinical models of pancreas cancer mice.
A new type of ras inhibitor
In this study, the researchers used RAS (EN) multiple selective inhibitors, the Daraxonrasib research agent (RMC-6236) and the RMC-7977 preclinical tool compound (both discovered by revolution medications, whose scientists contributed to the study). These inhibitors use a different mechanism of action from the majority Kras inhibitors (including the one in the previous study) is directed to the active forms or in the state of multiple of Ras Mutations
“The benefit of this” multiselective ‘approach is that inhibitors are designed to inhibit multiple Ras mutations, so if muta cancer and other types of Ras Mutation emerges, the treatment does not necessarily stop working, “Vanderheide explained.
The research team found that not only the multiple RAS inhibition was not only effective in preclinical pancreas cancer models, but it was even more effective when combined with immunotherapy. Using the combined approach, all mouse models had tumor contraction and half had a complete response, which means that the tumor was eliminated.
The research team used an immunocompetent model developed by Penn considered the gold standard worldwide to evaluate possible therapies for pancreatic ductal adenocarcinoma. This model allows the tumor to evolve spontaneously after the implementation, which allows to discern the impact of the drug on the surrounding tumor microenvironment. The research team found that multiple multiselective inhibition reformed the tumor microenvironment by attracting more T cells and other immune cells, which makes the tumor particularly receptive to immunotherapy.
Next steps and information about the clinical trial
DARAXONRASIB (RMC-6236) is already being tested in clinical trials in the United States. A clinical trial that proves ras (ON) inhibitors with other anti -cancer agents in certain patients with gastrointestinal solid tumors is now open in several places throughout the country, even in Penn Medicine. Click here for more information about the study.
“We hope that we are beginning to decipher the code in immunotherapy and Ras Therapy for pancreatic cancer, “said Vonderheide.” After decades of limited progress, it is encouraging to see new treatment approaches that reach the clinic for patients. “
The study was supported by Revolution Medicines, the National Institutes of Health (R01CA252225, R01CA276512, P30DK050306, P30CA016520) The Department of Defense (W81xWh2210730), the Center for Pathology and Molecular Images, a love for life, the center of Moscador for BRC and the Penn Penn Panc
Information for patients interested in joining a clinical trial: Visit the Information Service of the Abramson Center clinical trial Penn Medicine online information service or call 1-855-216-0098 to talk to a clinical trial browser.
Editor’s note: VONDERHEIDE is an inventor in patents related to cell immunotherapy of cancer and immune epitopes of Kras.